A Mab A Case Study In Bioprocess Development __top__ Jun 2026
The process begins by defining the , which outlines the desired clinical safety and efficacy of the antibody. From this, scientists identify Critical Quality Attributes (CQAs) —physical, chemical, or biological properties that must be within an appropriate limit to ensure product quality.
Strategy: The scale-up was modeled keeping the volumetric mass transfer coefficient ( kLak sub cap L a ) constant between scales (
Modern CLD processes are rapid and high-throughput, leveraging automation to screen thousands of clones. A robust platform process can accelerate this stage, but it is not without risks; the chosen clone's stability and productivity must be verified early to avoid failures later in scale-up.
Upstream development focuses on the living "factory"—the cell line —and its growth environment. A Mab A Case Study In Bioprocess Development
For mAb-X, we utilized . This is the workhorse of mAb purification because Protein A binds specifically to the Fc region of antibodies, ignoring almost everything else (host cell proteins, DNA, viruses).
Future optimization work will explore the transition toward an end-to-end continuous manufacturing platform. This includes testing continuous multi-column chromatography (MCC) for the Protein A capture step, which promises to reduce resin costs, minimize footprint, and further increase production throughput.
Shifting the temperature down slowed cell proliferation but prolonged cell viability and increased specific productivity ( The process begins by defining the , which
Once a lead clone is selected, the work to refine its chemical and physical environment begins. A central challenge is maintaining while managing the buildup of toxic waste products like lactate and ammonia. A key strategy for A-mAb is the transition from a traditional fed-batch process to an intensified perfusion method. In a case study with a similar mAb for osteoporosis treatment, Enzene Biosciences documented the dramatic benefits of this shift. By implementing an intensified perfusion process, productivity jumped from 15g in a 5L fed-batch to 48g in a 2L perfusion and an astonishing 730g in a 30L perfusion system. This highlights the potential of process intensification to unlock orders-of-magnitude gains in yield.
: Leveraging "prior knowledge" from similar molecules (platform technologies) significantly accelerates development.
From the QTPP, engineers identify —the chemical, physical, or biological properties that must remain within strict limits to ensure patient safety and efficacy. For mAb A, the CQAs include: A robust platform process can accelerate this stage,
Defining the essential performance characteristics of the drug from a patient-centric perspective.
For bioprocess engineers and scientists, every new Mab is a new case study. And every case study, like Mab-X, is a step toward safer, more affordable biologics for patients worldwide.
By using Design of Experiments (DoE), developers gain a deeper understanding of how process parameters interact.